GSK licensed two small interfering RNA (siRNA) assets from Frontier Biotechnologies in a deal that starts with a $40 million up‑front payment and can reach roughly $1 billion with milestones, the companies announced. Frontier retains progress on one candidate in Phase I in China and is completing IND‑enabling work on the other. Under the agreement, GSK will assume global development, manufacturing and commercialization responsibilities once clinical thresholds are met; Frontier stands to receive development and sales milestones plus royalties. The deal broadens GSK’s oligonucleotide portfolio alongside other recent oligo and siRNA transactions. For oligonucleotide developers, the transaction highlights continued Big Pharma appetite for externally sourced RNA therapeutics to fill immunology and rare‑disease pockets of their pipelines.